These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 24798787)
1. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration. Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787 [TBL] [Abstract][Full Text] [Related]
2. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Gong JH; Liu XJ; Li Y; Zhen YS Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160 [TBL] [Abstract][Full Text] [Related]
3. Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways. Chen Y; Wang S; Lu X; Zhang H; Fu Y; Luo Y Blood; 2011 Jun; 117(23):6392-403. PubMed ID: 21482707 [TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055 [TBL] [Abstract][Full Text] [Related]
5. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391 [TBL] [Abstract][Full Text] [Related]
6. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma. Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278 [TBL] [Abstract][Full Text] [Related]
7. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052 [TBL] [Abstract][Full Text] [Related]
8. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436 [TBL] [Abstract][Full Text] [Related]
9. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab. Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413 [TBL] [Abstract][Full Text] [Related]
10. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy. Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780 [TBL] [Abstract][Full Text] [Related]
12. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
13. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300 [TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number. De Cesare M; Lauricella C; Veronese SM; Cominetti D; Pisano C; Zunino F; Zaffaroni N; Zuco V Clin Cancer Res; 2014 Feb; 20(4):995-1006. PubMed ID: 24327272 [TBL] [Abstract][Full Text] [Related]
15. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410 [TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035 [TBL] [Abstract][Full Text] [Related]
17. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Pan L; Tighiouart M; Shin HJ; Koenig L; Park W; Rycroft D; Nannapaneni S; Wang Y; Chen ZG; Shin DM Int J Cancer; 2012 Aug; 131(4):956-69. PubMed ID: 21918971 [TBL] [Abstract][Full Text] [Related]
18. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944 [TBL] [Abstract][Full Text] [Related]
19. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice. Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]